Natural history definition and a suggested clinical approach to Buerger's disease: A case-control study with survival analysis

Vascular

Volumn 20, Issue 4, 2012, Pages 198-202

  Fazeli, Bahare ^a   Ravari, Hassan ^b   Assadi, Reza ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amputation; Natural history; Thromboangiitis obliterans; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; PROSTACYCLIN DERIVATIVE; TICLOPIDINE;

ADULT; AMPUTATION; ARTICLE; BUERGER DISEASE; CASE CONTROL STUDY; CIGARETTE SMOKING; DISEASE ACTIVITY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RISK FACTOR; SMOKING CESSATION; SURVIVAL;

ADULT; AMPUTATION; DISEASE PROGRESSION; FEMALE; HUMANS; IRAN; KAPLAN-MEIER ESTIMATE; LIMB SALVAGE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SMOKING; SMOKING CESSATION; THROMBOANGIITIS OBLITERANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866177357     PISSN: 17085381     EISSN: 1708539X     Source Type: Journal    
DOI: 10.1258/vasc.2011.oa0323     Document Type: Article

References (20)

1. Fazeli B, Rezaee SA. A review on thromboangiitis obliterans pathophysiology: thrombosis and angiitis, which is to blame? Vascular 2011;19:116-29
2. Fazeli B. Buerger's disease as an indicator of socioeconomic development in different societies, a cross-sectional descriptive study in the North-East of Iran. Arch Med Sci 2010;6:343-7
3. Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 2006;18:18-24 (Pubitemid 43740401)
4. Shigematsu H, Shigematsu K. Factors affecting the long-term outcome of Buerger's disease (thromboangiitis obliterans). Int Angiol 1999;18:58-64 (Pubitemid 29253670)
5. Nielubowicz J, Rosnowski A, Pruszynski B, Przetakiewicz Z, Potemkowski A. Natural history of Buerger's disease. J Cardiovasc Surg (Torino) 1980;21:529-40 (Pubitemid 11214953)
6. Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol 1998;66(Suppl 1):S243-5; discussion S247
7. Fazeli B, Modaghegh H, Ravrai H, Kazemzadeh G. Thrombophlebitis migrans as a footprint of Buerger's disease: a prospective-descriptive study in north-east of Iran. Clin Rheumatol 2008;27:55-7 (Pubitemid 350182678)
8. Lazarides MK, Georgiadis GS, Papas TT, Nikolopoulos ES. Diagnostic criteria and treatment of Buerger's disease: a review. Int J Low Extrem Wounds 2006;5:89-95 (Pubitemid 43726037)
9. Piazza G, Creager MA. Thromboangiitis obliterans. Circulation 2010;121:1858-61
10. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11
11. Czarnacki M, Zdrojowy K, Adamiec R. Review of current etiopathogenic data of Buerger disease. Pol Merkur Lekarski 2002;13:263-5
12. Reny JL, Cabane J. Buerger's disease or thromboangiitis obliterans. Rev Med Interne 1998;19:34-43
13. Bozkurt AK, Köksal C, Demirbas MY, et al. Turkish Buerger's Disease Research Group. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol 2006;25:162-8 (Pubitemid 44043714)
14. Noël B, Panizzon RG. Use of duplex ultrasonography in the treatment of thromboangiitis obliterans with iloprost. Dermatology 2004;208:238-40
15. Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002;62:107-33 (Pubitemid 34169428)
16. Musiał J, Wilczyńska M, Sładek K, Cierniewski CS, Nizankowski R, Szczeklik A. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 1986;31:61-70 (Pubitemid 16165375)
17. Chang TC, Huang CJ, Tam K, et al. Stabilization of hypoxia-inducible factor-1{alpha} by prostacyclin under prolonged hypoxia via reducing reactive oxygen species level in endothelial cells. J Biol Chem 2005;280:36567-74 (Pubitemid 41587732)
18. Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo. Angiology 1982;33:357-67 (Pubitemid 12088649)
19. Palomo Arellano A, Gómez Tello V, Parilla Herranz P, Castilla Plaza A, Marcos Sánchez F, Durán Pérez-Navarro A. Buerger's disease starting in the upper extremity. A favorable response to nifedipine treatment combined with stopping tobacco use. An Med Interna 1990;7:307-8
20. Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol Rep 2008;60:3-11 (Pubitemid 351586537)